{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Triple+Negative+Breast+Cancer", "query": { "condition": "Triple Negative Breast Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 748, "total_pages": 75, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Triple+Negative+Breast+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-07T13:20:42.022Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05383170", "title": "A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Head and Neck Squamous Cell Carcinoma", "Advanced Breast Cancer", "Advanced Melanoma" ], "interventions": [ { "name": "CyPep-1", "type": "DRUG" }, { "name": "Pembrolizumab 25 MG/ML [KEYTRUDA®]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cytovation AS", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2023-03-21", "completion_date": "2024-09-23", "has_results": true, "last_update_posted_date": "2025-11-28", "last_synced_at": "2026-06-07T13:20:42.022Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Duarte, California • Detroit, Michigan + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05383170" }, { "nct_id": "NCT02926690", "title": "Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer" ], "interventions": [ { "name": "OTS167PO", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoTherapy Science, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2017-05-29", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-06-07T13:20:42.022Z", "location_count": 8, "location_summary": "Norwalk, Connecticut • Atlanta, Georgia • Honolulu, Hawaii + 4 more", "locations": [ { "city": "Norwalk", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02926690" }, { "nct_id": "NCT02637531", "title": "A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors (Part A/B/C/D)", "Non-small Cell Lung Cancer (Part E)", "Melanoma (Part E)", "Squamous Cell Cancer of the Head and Neck (Part E)", "Triple Negative Breast Cancer (Part F)", "Adrenocortical Carcinoma (Part G)", "Mesothelioma (Part G)", "High-circulating Myeloid-derived Suppressor Cells (Part H)" ], "interventions": [ { "name": "IPI-549 (eganelisib)", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Infinity Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 219, "start_date": "2015-12", "completion_date": "2022-12", "has_results": false, "last_update_posted_date": "2022-04-04", "last_synced_at": "2026-06-07T13:20:42.022Z", "location_count": 11, "location_summary": "San Diego, California • Santa Monica, California • Port Saint Lucie, Florida + 6 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02637531" }, { "nct_id": "NCT06700070", "title": "A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Soft Tissue Sarcoma Adult", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "PBA-0111", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pure Biologics S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2025-03-27", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2025-08-11", "last_synced_at": "2026-06-07T13:20:42.022Z", "location_count": 1, "location_summary": "Shreveport, Louisiana", "locations": [ { "city": "Shreveport", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06700070" }, { "nct_id": "NCT05660083", "title": "Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-negative Breast Cancer", "Metastatic Breast Cancer", "Metaplastic Breast Carcinoma", "TNBC - Triple-Negative Breast Cancer" ], "interventions": [ { "name": "L-NMMA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2023-01-12", "completion_date": "2028-12-02", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-06-07T13:20:42.022Z", "location_count": 3, "location_summary": "Bethesda, Maryland • Houston, Texas", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05660083" }, { "nct_id": "NCT06171789", "title": "PRO1107 in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Endometrial Cancer", "Ovarian Cancer", "Triple Negative Breast Cancer", "GastroEsophageal Cancer", "Non-small Cell Lung Cancer", "Urothelial Carcinoma" ], "interventions": [ { "name": "GEN1107", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2024-01-03", "completion_date": "2025-08-18", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-06-07T13:20:42.022Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Sarasota, Florida • Boston, Massachusetts + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06171789" }, { "nct_id": "NCT03219268", "title": "A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Hematologic Neoplasms", "Ovarian Cancer", "HER2-positive Advanced Solid Tumors", "Non Small Cell Lung Cancer", "Small-cell Lung Cancer", "Squamous Cell Carcinoma of Head and Neck", "Cholangiocarcinoma", "Cervical Cancer", "TNBC - Triple-Negative Breast Cancer" ], "interventions": [ { "name": "tebotelimab 1 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 3 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 10 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 30 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 120 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 300 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 400 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 600 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 800 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 1200 mg", "type": "BIOLOGICAL" }, { "name": "margetuximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 277, "start_date": "2017-08-18", "completion_date": "2023-02-08", "has_results": false, "last_update_posted_date": "2023-12-21", "last_synced_at": "2026-06-07T13:20:42.022Z", "location_count": 15, "location_summary": "Gilbert, Arizona • Los Angeles, California • Newport Beach, California + 11 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03219268" }, { "nct_id": "NCT01421472", "title": "A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "ER Positive, Her2 Negative Breast Cancer Patients", "Triple Negative Breast Cancer Patients" ], "interventions": [ { "name": "MM-121", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 196, "start_date": "2011-08", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2016-05-03", "last_synced_at": "2026-06-07T13:20:42.022Z", "location_count": 38, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Tuscon, Arizona + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tuscon", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Oxnard", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01421472" }, { "nct_id": "NCT07318805", "title": "A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Breast Cancer", "Metastatic Breast Cancer (HR+/ HER2-)", "Colorectal Cancer", "Metastatic Colorectal Adenocarcinoma", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "PF-08032562", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2025-12-23", "completion_date": "2030-04-14", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-06-07T13:20:42.022Z", "location_count": 9, "location_summary": "Duarte, California • Grand Rapids, Michigan • Conroe, Texas + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Conroe", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07318805" }, { "nct_id": "NCT05867251", "title": "Study of AVZO-021 in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "HR+/HER2- Breast Cancer", "HR+, HER2-, Advanced Breast Cancer", "CCNE1 Amplification", "Epithelial Ovarian Cancer", "Primary Peritoneal Cancer", "Fallopian Tube Cancer", "Endometrial Cancer", "TNBC - Triple-Negative Breast Cancer" ], "interventions": [ { "name": "AVZO-021", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Sacituzumab Govitecan-hziy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avenzo Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 430, "start_date": "2023-08-30", "completion_date": "2030-01-31", "has_results": false, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-06-07T13:20:42.022Z", "location_count": 11, "location_summary": "New Haven, Connecticut • Sarasota, Florida • Tampa, Florida + 8 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Mineola", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05867251" } ] }